Used in targeted cancer therapies, particularly for tumors expressing CLDN6 (Claudin-6), such as certain testicular, ovarian, and pediatric cancers. This antibody serves as a reference for developing antibody-drug conjugates (ADCs) and chimeric antigen receptor (CAR) T-cell therapies by specifically binding to CLDN6 on cancer cell surfaces. It enables precise targeting of malignant cells while sparing healthy tissues, supporting research in tumor imaging, drug delivery, and immunotherapy efficacy assessment. Its high specificity makes it valuable in preclinical studies for evaluating therapeutic candidates and diagnostic tools.